Seyed Ahmad Hosseini; Meysam Alipour; Mehrnoosh Zakerkish; Bahman Cheraghian; Pegah Ghandil
Volume 20, Issue 12 , December 2018, , Pages 1-7
Abstract
Background: The role of FTO-rs9939609 gene variants in response to the Epigallocatechin-Gallate (EGCG) intervention remains unclear. Objectives: The present study aimed at investigating the gene-treatment interaction of FTO-rs9939609 gene polymorphism and EGCG intervention on anthropometric indexes, ...
Read More
Background: The role of FTO-rs9939609 gene variants in response to the Epigallocatechin-Gallate (EGCG) intervention remains unclear. Objectives: The present study aimed at investigating the gene-treatment interaction of FTO-rs9939609 gene polymorphism and EGCG intervention on anthropometric indexes, fasting blood sugar, and insulin resistance/sensitivity in patients with Type 2 Dia- betes Mellitus (T2DM). Methods: This double-blind, randomized, placebo-controlled study was conducted on 66 patients (aged 20 to 60 years) with T2DM in Iran, from August 2017 to March 2018. Individuals were randomly block allocated to three groups. Group 1 received 300 mg EGCG (n = 22, TT genotype), Group 2 received 300 mg EGCG (n = 22, AA + AT genotypes), Group 3 received the placebo (n = 22). Two monthsfollowing the intervention, Waist-Hip Ratio (WHR), A Body Shape Index (ABSI), Fasting Blood Sugar (FBS), and insulin levels, as well as Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) and Quantitative Insulin Sensitivity Check Index (QUICKI) were evalu- ated. The FTO-rs9939609 polymorphism was genotyped by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP). Results: In both EGCG groups, a significant reduction in WHR was observed after the intervention compared with baseline (P < 0.05), with no significant differences in other parameters. The FTO-rs9939609 polymorphism showed no gene-treatment interac- tion in response to EGCG. Conclusions: This study suggests that administration of EGCG supplement for two months may provide anti-obesity effects in pa- tients with T2DM. However, the FTO-rs9939609 polymorphism was not associated with the change in anthropometric and glycemicstatus after EGCG intervention.
Mehrnoosh Zakerkish; Fatemeh Amiri; Nastaran Majdi Nasab; Ali Ghorbani
Volume 19, Issue 8 , August 2017, , Pages 1-7
Abstract
Background: Diabetic peripheral neuropathic pain (DPNP) is a common type of diabetic neuropathy. Blood sugar control is the first step for management of DPNP and drug treatment may be prescribed for the pain relief.Objectives: This study assessed the efficacy and safety of duloxetine and nortriptyline ...
Read More
Background: Diabetic peripheral neuropathic pain (DPNP) is a common type of diabetic neuropathy. Blood sugar control is the first step for management of DPNP and drug treatment may be prescribed for the pain relief.Objectives: This study assessed the efficacy and safety of duloxetine and nortriptyline in patients with DPNP.Methods: This double-blind randomized clinical trial was conducted in the diabetes clinic of Golestan Hospital (Ahvaz, Iran). Convenience sampling and simple random allocation were used in the study. 134 patients with DPNP were randomly divided into two groups (67 patients in each group). The duloxetine group received 30 to 60 mg/day and nortriptyline group received 25 to 75 mg/day for a period of 6 weeks. Pain assessment was conducted based on a Visual analogue scale (VAS) and drug side effects were assessed on a weekly basis.Results: The study showed that both groups had significant reduction in pain severity at the end of the study (P < 0.05). The proportion of patients achieving 50% reduction in pain severity was significantly greater in the duloxetine group than the nortriptyline group (P < 0.05). The treatment side effects observed in the two groups were not significantly different (P = 0.298).Conclusions: Monotherapy with duloxetine and nortriptyline is safe and effective in the management of patients with DPNP.
